XML 68 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and Divestitures - Narrative (Details)
$ in Thousands
12 Months Ended 24 Months Ended
Sep. 27, 2022
USD ($)
payment
Jun. 13, 2022
USD ($)
Jun. 28, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
May 15, 2021
USD ($)
Business Acquisition [Line Items]                
Contingent consideration liability       $ 44,022 $ 9,814      
Proceeds from sale of assets       12,434 224,909 $ 1,400    
Goodwill       2,536,730 2,504,202 2,585,966    
Acquisitions, contingent consideration, liability       43,168 0 0    
Late Stage Development Company                
Business Acquisition [Line Items]                
Payments to acquire productive assets   $ 22,800            
Asset acquisition, contingent consideration arrangements, range of outcomes, high   $ 26,200            
Useful life of Intangible assets, in years   15 years            
Standard Bariatrics                
Business Acquisition [Line Items]                
Business combination, consideration transferred $ 211,800              
Fair value of consideration transferred 173,000              
Contingent consideration liability 38,800              
Aggregate contingent consideration amount $ 130,000              
Number of milestone payments | payment 3              
Business combination, contingent consideration, period 3 years              
Business combination, acquisition related costs       1,300        
Goodwill $ 71,420              
Intangible assets $ 154,450              
Standard Bariatrics | Maximum                
Business Acquisition [Line Items]                
Contingent consideration liability       130,000        
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations                
Business Acquisition [Line Items]                
Disposal group, including discontinued operation, consideration               $ 286,000
Disposal group, including discontinued operation, working capital               $ 12,000
Proceeds from sale of assets     $ 259,000          
Revenue attributable to respiratory business         60,700 $ 138,500    
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations | Medline Manufacturing And Supply Transition Agreement                
Business Acquisition [Line Items]                
Revenue from related parties       $ 79,100 $ 51,100      
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations | Forecast                
Business Acquisition [Line Items]                
Proceeds from sale of assets             $ 15,000